Radient Pharma Refines Divestiture Plan for Jade Pharma

Radient Pharma now plans to acquire a “well-managed, China-based” pharmaceutical company to take over management of its rogue Jade Pharmaceuticals subsidiary. The combined company, which will have a broader base of products than Jade’s current offerings, will seek financing and eventually be listed publically on a US exchange. More details... Stock Symbol: (NYSE AMEX: RPC)